Panel: Dismissal Properly Denied In Antitrust Row Over Drug Patent Listings
NEW YORK — Allegations that the maker of the brand name drug ACTOS mischaracterized the scope of its combination patents to gain an anti-competitive edge will proceed in New York federal...To view the full article, register now.
Already a subscriber? Click here to view full article